GlaxoSmithKline plc (NYSE:GSK) Shares Bought by Point72 Asset Management L.P.

Share on StockTwits

Point72 Asset Management L.P. raised its position in GlaxoSmithKline plc (NYSE:GSK) by 362.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,105,172 shares of the pharmaceutical company’s stock after acquiring an additional 866,015 shares during the quarter. Point72 Asset Management L.P.’s holdings in GlaxoSmithKline were worth $44,229,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Berman Capital Advisors LLC raised its position in shares of GlaxoSmithKline by 58.1% during the 2nd quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. Sigma Planning Corp raised its position in shares of GlaxoSmithKline by 0.8% during the 2nd quarter. Sigma Planning Corp now owns 32,090 shares of the pharmaceutical company’s stock valued at $1,284,000 after buying an additional 250 shares during the period. Trillium Asset Management LLC raised its position in shares of GlaxoSmithKline by 2.2% during the 2nd quarter. Trillium Asset Management LLC now owns 11,519 shares of the pharmaceutical company’s stock valued at $461,000 after buying an additional 252 shares during the period. CIBC Private Wealth Group LLC raised its position in shares of GlaxoSmithKline by 1.8% during the 2nd quarter. CIBC Private Wealth Group LLC now owns 14,824 shares of the pharmaceutical company’s stock valued at $593,000 after buying an additional 261 shares during the period. Finally, Essex Financial Services Inc. raised its position in shares of GlaxoSmithKline by 4.0% during the 2nd quarter. Essex Financial Services Inc. now owns 6,990 shares of the pharmaceutical company’s stock valued at $280,000 after buying an additional 269 shares during the period. Institutional investors own 11.12% of the company’s stock.

Shares of GlaxoSmithKline stock traded up $0.31 during trading hours on Friday, reaching $41.63. 2,908,350 shares of the company were exchanged, compared to its average volume of 2,007,830. GlaxoSmithKline plc has a 1 year low of $36.41 and a 1 year high of $42.49. The stock’s fifty day moving average is $41.03 and its 200 day moving average is $40.60. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71. The firm has a market cap of $102.41 billion, a PE ratio of 13.17, a PEG ratio of 1.98 and a beta of 0.70.

GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. The firm had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. Research analysts expect that GlaxoSmithKline plc will post 2.94 earnings per share for the current year.

Several research firms have recently commented on GSK. Cowen reaffirmed a “hold” rating and set a $45.00 price target on shares of GlaxoSmithKline in a research report on Monday, June 10th. Societe Generale raised shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, August 13th. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and an average target price of $41.79.

In other news, Director Plc Glaxosmithkline bought 333,333 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was purchased at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.00% of the company’s stock.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: How to invest using market indexes

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Penske Automotive Group  Upgraded to Hold at Zacks Investment Research
Penske Automotive Group Upgraded to Hold at Zacks Investment Research
Nordic American Tanker  Upgraded to “Hold” at Zacks Investment Research
Nordic American Tanker Upgraded to “Hold” at Zacks Investment Research
LSB Industries  Upgraded to “Buy” at Zacks Investment Research
LSB Industries Upgraded to “Buy” at Zacks Investment Research
Intrepid Potash  Upgraded by ValuEngine to Sell
Intrepid Potash Upgraded by ValuEngine to Sell
Guggenheim Begins Coverage on Cardiovascular Systems
Guggenheim Begins Coverage on Cardiovascular Systems
BioSpecifics Technologies  Upgraded to “Buy” by Zacks Investment Research
BioSpecifics Technologies Upgraded to “Buy” by Zacks Investment Research


© 2006-2019 Ticker Report